Alembic Pharma's Vadodara Bioequivalence Facility Clears USFDA Inspection With Zero Observations
Written By : sheeba farhat
Published On 2026-09-12 13:19 GMT | Update On 2026-09-12 13:19 GMT
New Delhi: Alembic Pharmaceuticals on Friday said the US health regulator has completed an unannounced inspection at its bioequivalence facility in Vadodara, Gujarat, with zero observation.
In a regulatory filing, the company said the United States Food and Drug Administration (USFDA) carried out the onsite bioequivalence inspection from August 31, 2026, to September 10, 2026.
The inspection concluded with no Form 483 observations, it added.
In USFDA parlance, an FDA Form 483 is issued to a firm's management at the conclusion of an inspection when investigators observe conditions that may violate the Food, Drug, and Cosmetic Act and related regulations. No observations under this rule indicate a clean outcome.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.